Hydroxy metabolite concentrations: role of renal clearance

  • William Z. Potter
  • Elizabeth A. Lane
  • Matthew V. Rudorfer


It is generally emphasized that basic lipophilic psychoactive drugs are cleared primarily through metabolism, not renal clearance (Potter et al., 1981). Kidney disease or other sources of alterations of renal clearance are not reported to affect plasma concentrations of drugs such as the tricyclic antidepressants, although the clearance of unmetabolized drugs such as lithium will clearly be affected (Amdisen, 1977). From any but an academic point of view this would be the limit of interest in renal clearance if extensively metabolized parent drugs were the only biologically active forms.


Lithium Noradrenaline Propranolol Diphenylhydantoin Tricyclic 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Alexanderson, B. and Borgå, O. (1973). Urinary excretion of nortriptyline and five of its metabolites in man after single and multiple doses. Eur. J. Clin. Pharmacol., 5, 174–80CrossRefGoogle Scholar
  2. Amdisen, A. (1977). Serum level monitoring and clinical pharmacokinetics of lithium. Clin. Pharmacokin., 2, 73–92CrossRefGoogle Scholar
  3. Bertilsson, L., Mellström, B. and Sjöqvist, F. (1979). Pronounced inhibition of noradrenaline uptake by 10-hydroxy-metabolites of nortriptyline. Life Sci., 25, 1285–92CrossRefPubMedGoogle Scholar
  4. Braithwaite, R.A. and Dawling, S. (1981). The pharmacokinetics and metabolism of tricyclic antidepressant drugs in patients with chronic renal failure. In Clinical Pharmacology in Psychiatry; Neuroleptic and Antidepressant Research (ed. E. Usdin, S.G. Dahl, L.F. Gram and O. Lingjaerde), Macmillan, London, pp. 285–95Google Scholar
  5. Crammer, J.L., Scott, B. and Rolfe, B. (1969). Metabolism of 14Cimipramine. II. Urinary metabolites in man. Psychopharmacologia (Berlin), 15, 207–25PubMedGoogle Scholar
  6. Dawling, S., Lynn, K., Rosser, R. and Braithwaite, R. (1981). The pharmacokinetics of nortriptyline in patients with chronic renal failure. Br. J. Clin. Pharmacol., 12, 39–45CrossRefGoogle Scholar
  7. Garattini, S., Marcucci, F. and Mussini, E. (1975). Biotransformation of drugs to pharmacologically active metabolites. In Handbook of Experimental Pharmacology, XXVIII/3, Concepts in Biochemical Pharmacology (ed. J.R. Gillette and J.R. Mitchell), Springer-Verlag, Berlin, pp. 113–29CrossRefGoogle Scholar
  8. Hoffmann, K.-J., Regårdh, C.-G., Aurell, M., Ervik, M. and Jordö, L. (1980). The effect of impaired renal function on the plasma concentration and urinary excretion of metoprolol metabolites. Clin. Pharmacokin., 5, 181–91CrossRefGoogle Scholar
  9. Kitanaka, I., Ross, R.J., Cutler, N.R., Zavadil, A.P., III, and Potter, W.Z. (1982). Altered hydroxydesipramine concentrations in elderly depressed patients. Clin. Pharmacol. Ther., 31, 51–5CrossRefPubMedGoogle Scholar
  10. Kleinman, J.E., Nasrallah, H.A., Bigelow, L.B., Rogol, A.D., Zalcman, S., Wyatt, R.J. and Gillin, J.C. (1978). 7-Hydroxychlorpromazine, an active metabolite of chlorpromazine. Presented at American Psychiatric Association Annual Meeting, May 8–12, Atlanta, Georgia, Abstract No. NR29Google Scholar
  11. Kragh-Sørensen, P., Borgå, O., Garle, M., Bolvig Hansen, L., Hansen, C.E., Hvidberg, E.F., Larsen, N.-E. and Sjöqvist, F. (1977). Eur. J. Clin Pharmacol., 11, 479–83CrossRefPubMedGoogle Scholar
  12. Levy, G. (1980). Effect of plasma protein binding on renal clearance of drugs. J. Pharm. Sci., 69, 482–3CrossRefPubMedGoogle Scholar
  13. Linnoila, M., Insel, T., Kilts, C., Potter, W.Z. and Murphy, D.L. (1982). Plasma steady-state concentrations of hydroxylated metabolites of clomipramine. Clin. Pharmacol. Ther., 32, 208–11CrossRefPubMedGoogle Scholar
  14. Lundborg, P., Regårdh, C.G. and Landahl, S. (1982). The pharmacokinetics of metoprolol in healthy elderly individuals (Abstract). Clin. Pharmacol. Ther., 31, 246Google Scholar
  15. Lynn, K., Braithwaite, R., Dawling, S. and Rosser, R. (1981). Comparison of the serum protein binding of maprotiline and phenytoin in uremic patients on haemodialysis. Eur. J. Clin. Pharmacol., 19, 73–7CrossRefPubMedGoogle Scholar
  16. Mellström, B., Bertilsson, L., Säwe, J., Schulz, H.-U. and Sjöqvist, F. (1981). E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation. Clin. Pharmacol. Ther., 30, 189–93CrossRefPubMedGoogle Scholar
  17. Piafsky, K.M., Borgå, O., Odar-Cederlöf, I., Johansson, C. and Sjöqvist, F. (1978). Increased plasma protein binding of propranolol and chlorpromazine mediated by disease-induced elevation of α1-acid glycoprotein. New Engl. J. Med., 299, 1435–9CrossRefPubMedGoogle Scholar
  18. Potter, W.Z., Bertilsson, L. and Sjöqvist, F. (1981). Clinical pharmacokinetics of psychotropic drugs: fundamental and practical aspects. In The Handbook of Biological Psychiatry, (ed. H.M. Van Praag, O. Rafaelsen, M. Lader and A. Sacher) Marcel Dekker, New York, pp. 71–134Google Scholar
  19. Potter, W.Z., and Calil, H.M. (1981). Metabolites of tricyclic antidepressants — biological activity and clinical implications. In Clinical Pharmacology in Psychiatry (ed. E. Usdin), Elsevier/North-Holland, New York, pp. 311–24Google Scholar
  20. Potter, W.Z., Calil, H.M., Sutfin, T., Zavadil, A.P., III, Jusko, W.J., Rapoport, J. and Goodwin, F.K. (1982). Active metabolites of imipramine and desipramine in man. Clin. Pharmacol. Ther., 31, 393–401CrossRefPubMedGoogle Scholar
  21. Reidenberg, M.M., Odar-Cederlöf, I., von Bahr, C., Borgå, O. and Sjöqvist, F. (1971). Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function. New Engl. J. Med., 285, 264–7CrossRefPubMedGoogle Scholar
  22. Sutfin, T.A., and Jusko, W.J. (1979). High-performance liquid chromatographic assay for imipramine, desipramine, and their 2-hydroxylated metabolites. J. Pharm. Sci., 68, 703–5CrossRefPubMedGoogle Scholar
  23. Träskman, L., Asberg, M., Bertilsson, L., Cronholm, B., Mellström, B., Neckers, L.M., Sjöqvist, F., Thorén, P. and Tybring, G. (1979). Plasma levels of chlorimipramine and its demethyl metabolite during treatment of depression. Clin. Pharmacol. Ther., 26, 600–10PubMedGoogle Scholar
  24. Vestal, R.E. (1978). Drug use in the elderly: a review of problems and special considerations. Drugs, 16, 358–82CrossRefPubMedGoogle Scholar

Copyright information

© The contributors 1983

Authors and Affiliations

  • William Z. Potter
    • 1
  • Elizabeth A. Lane
    • 1
  • Matthew V. Rudorfer
    • 1
  1. 1.Clinical Psychobiology Branch, National Institute of Mental Health, and Pharmacological Sciences ProgramNational Institute of General Medical SciencesBethesdaUSA

Personalised recommendations